Insider · CIK 0001192591
Charles J Homcy
Files at BBIO (BridgeBio Pharma, Inc.), MAZE (Maze Therapeutics, Inc.). First filing Aug 12, 2025, latest Aug 12, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BBIO: BridgeBio Pharma, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 40Moderate | BridgeBio Pharma, Inc. | $14M 300,000 shares | -25% | +108% from low-5% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 8, 2025 | BBIO BridgeBio Pharma, Inc. | SOpen-market sale Common Stock10b5-1 | -191,662 | $45.87 | $8.8M | 1,025,012 | Aug 12, 2025 |
| Aug 8, 2025 | BBIO BridgeBio Pharma, Inc. | SOpen-market sale Common Stock10b5-1 | -58,338 | $46.64 | $2.7M | 966,674 | Aug 12, 2025 |
| Aug 11, 2025 | BBIO BridgeBio Pharma, Inc. | SOpen-market sale Common Stock10b5-1 | -50,000 | $48.00 | $2.4M | 916,674 | Aug 12, 2025 |
| Jun 27, 2025 | BBIO BridgeBio Pharma, Inc. | GGift Common Stock | -20,000 | $0.00 | $0 | 1,216,674 | Jun 30, 2025 |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | AGrant or award Common Stock | +6,589 | $0.00 | $0 | 1,236,674 | Jun 24, 2025 |
| Jun 20, 2025 | BBIO BridgeBio Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,425 | $0.00 | $0 | 8,425 | Jun 24, 2025 |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | CConversion Common Stock | +8,807 | - | - | 37,330 | Feb 4, 2025 |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | CConversion Common Stock | +20,717 | - | - | 58,047 | Feb 4, 2025 |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | CConversion Common Stockindirect: By Trust | +7,422 | - | - | 7,422 | Feb 4, 2025 |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | CConversion Series B Preferred Stockderivative | -72,727 | - | - | 0 | Feb 4, 2025 |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | CConversion Series C Preferred Stockderivative | -169,405 | - | - | 0 | Feb 4, 2025 |
| Feb 3, 2025 | MAZE Maze Therapeutics, Inc. | CConversion Series D-1 Preferred Stockderivativeindirect: By Trust | -71,564 | - | - | 0 | Feb 4, 2025 |
| Nov 26, 2024 | MAZE Maze Therapeutics, Inc. | CConversion Series D-1 Preferred Stockderivativeindirect: By Trust | +71,564 | - | - | 7,422 | Feb 4, 2025 |
| Nov 26, 2024 | MAZE Maze Therapeutics, Inc. | CConversion 8% Convertible Note due 2026derivativeindirect: By Trust | - | $78,961.64 | - | - | Feb 4, 2025 |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +80,385 | $0.00 | $0 | 80,385 | Feb 4, 2025 |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -80,385 | - | - | 0 | Feb 4, 2025 |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,704 | $0.00 | $0 | 5,704 | Feb 4, 2025 |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,704 | - | - | 0 | Feb 4, 2025 |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +46,675 | $0.00 | $0 | 46,675 | Feb 4, 2025 |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -46,675 | - | - | 0 | Feb 4, 2025 |
| Dec 9, 2024 | MAZE Maze Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +45,638 | $0.00 | $0 | 45,638 | Feb 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.